Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Disorders of the Skeletal Muscle

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mutation-specific cellular mechanisms in Drosophila models of ATL1-associated hereditary spastic paraplegia.

Neurobiology of disease·2026

Same author

Centrosome linker protein CEP68 modulates cellular stress responses via nuclear condensate formation and HSP27 interaction.

iScience·2026

Same author

Dynamic conformational ensembles of soluble Tau encode neuronal toxicity prior to aggregation.

bioRxiv : the preprint server for biology·2026

Same author

LXR agonist rescues synaptic dysfunction and degeneration in SPG3A patient-specific iPSC-derived neurons.

Acta neuropathologica communications·2025

Same author

Small peptide P110 mitigates axonal degeneration of SPG15 patient iPSC-derived neurons by targeting mitochondrial dysfunction.

Neurobiology of disease·2025

Same author

ER shaping closes the gap in wound healing.

Nature cell biology·2025

Search research articles

Related Experiment Video

Updated: Jul 12, 2026

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

Rewriting Duchenne muscular dystrophy therapy.

Paloma Gonzalez-Perez¹, Craig Blackstone¹

¹Department of Neurology, Mass General Brigham and Harvard Medical School, Boston, MA 02114, USA.

|July 9, 2026

Summary

Researchers developed a novel RNA-editing therapy for Duchenne muscular dystrophy that uses exon skipping. This dual-action approach may offer greater efficacy and less frequent dosing than current antisense oligonucleotide (ASO) treatments.

Area of Science:

Molecular Biology
Gene Therapy
Neuromuscular Disorders

Background:

Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration.
Current treatments, such as antisense oligonucleotide (ASO)-based exon skipping, face limitations in efficacy and dosing frequency.

Purpose of the Study:

To develop a novel therapeutic strategy for Duchenne muscular dystrophy.
To investigate a new exon-skipping, RNA-editing-based approach with a dual mechanism of action.

Main Methods:

Development of a novel RNA-editing therapeutic agent.
Utilizing both ADAR-dependent and ADAR-independent pathways for exon skipping.

Main Results:

The new therapy demonstrated exon-skipping capabilities.

More Related Videos

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

Related Experiment Videos

Last Updated: Jul 12, 2026

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

The dual mechanism shows potential for enhanced therapeutic effects.

Conclusions:

This novel RNA-editing therapy offers a promising alternative for Duchenne muscular dystrophy treatment.
The dual mechanism may lead to improved efficacy and reduced dosing frequency compared to existing ASO therapies.